+

WO2006002378A3 - Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods - Google Patents

Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods Download PDF

Info

Publication number
WO2006002378A3
WO2006002378A3 PCT/US2005/022501 US2005022501W WO2006002378A3 WO 2006002378 A3 WO2006002378 A3 WO 2006002378A3 US 2005022501 W US2005022501 W US 2005022501W WO 2006002378 A3 WO2006002378 A3 WO 2006002378A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
methods
regions
cancerous
therapeutic targets
Prior art date
Application number
PCT/US2005/022501
Other languages
French (fr)
Other versions
WO2006002378A2 (en
Inventor
Jeffrey W Strovel
Colyn B Cain
Stephen K Horrigan
Meena Augustus
Original Assignee
Avalon Pharmaceuticals
Jeffrey W Strovel
Colyn B Cain
Stephen K Horrigan
Meena Augustus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Jeffrey W Strovel, Colyn B Cain, Stephen K Horrigan, Meena Augustus filed Critical Avalon Pharmaceuticals
Publication of WO2006002378A2 publication Critical patent/WO2006002378A2/en
Publication of WO2006002378A3 publication Critical patent/WO2006002378A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for identifying antineoplastic agents by using their ability to modify expression of specific genes or the biological activity of polypeptides encoded by such genes, wherein said genes are located in specific chromosomal regions, called amplicons, or regions of interest, and the presence of such amplified regions within a cancerous cell, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions using these methods. Also encompassed are methods involving determining the modulated expression of the genes in these regions of interest (ROIs), or amplicons, as pharmacodynamic/pharmacogenetic/surrogate markers and/or for patient profiling prior to accrual for clinical trials/treatments based on the identification of these genes as validated gene/drug targets in various cancer tissue types.
PCT/US2005/022501 2004-06-23 2005-06-23 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods WO2006002378A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58169904P 2004-06-23 2004-06-23
US60/581,699 2004-06-23

Publications (2)

Publication Number Publication Date
WO2006002378A2 WO2006002378A2 (en) 2006-01-05
WO2006002378A3 true WO2006002378A3 (en) 2007-07-12

Family

ID=35782366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022501 WO2006002378A2 (en) 2004-06-23 2005-06-23 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods

Country Status (1)

Country Link
WO (1) WO2006002378A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029290A2 (en) * 2006-09-07 2008-03-13 Universidad De Salamanca Identification of cancer stem cells using genetic markers
WO2008106731A1 (en) * 2007-03-05 2008-09-12 The University Of Queensland A target for breast cancer therapy and/or diagnosis
WO2009131366A2 (en) * 2008-04-21 2009-10-29 한국생명공학연구원 Cdca5 as a diagnosis marker and therapeutic agent for gastric cancer or colorectal cancer
WO2009138392A1 (en) * 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
EP2313528A4 (en) 2008-07-21 2012-01-25 Neodiagnostix Inc Methods for the cytological analysis of cervical cells
KR20160039295A (en) * 2008-08-05 2016-04-08 도레이 카부시키가이샤 Cancer detection method
DK2322221T3 (en) 2008-08-05 2014-09-01 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCER
WO2011011527A2 (en) 2009-07-21 2011-01-27 Neodiagnostix, Inc. Method and system for automated image analysis in cancer cells
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PT2532743E (en) 2010-02-04 2015-08-04 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
RU2624029C2 (en) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Drugs for cancer treatment and/or prevention
HUE030103T2 (en) 2010-02-04 2017-04-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
ES2606173T3 (en) 2010-02-04 2017-03-23 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prevention of cancer
WO2011096519A1 (en) 2010-02-04 2011-08-11 東レ株式会社 Medicinal composition for treating and/or preventing cancer
JP6070191B2 (en) 2011-08-04 2017-02-01 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
AU2012290955B2 (en) 2011-08-04 2017-04-27 Toray Industries, Inc. Drug composition for cancer treatment and/or prevention
RU2595400C2 (en) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Pharmaceutical composition for treating and/or preventing malignant growth
MX348577B (en) 2011-08-04 2017-06-20 Toray Industries Cancer treatment and/or prevention drug composition.
PT2740489T (en) 2011-08-04 2017-01-10 Toray Industries Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
JP6065590B2 (en) 2011-08-04 2017-01-25 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
DK2818481T3 (en) 2012-02-21 2019-10-14 Toray Industries Pharmaceutical composition for the treatment and / or prevention of cancer
CN104169303B (en) 2012-02-21 2018-05-29 东丽株式会社 The treatment of cancer and/or prophylactic compositions
US9266958B2 (en) 2012-02-21 2016-02-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2818483B1 (en) 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
PT2832366T (en) 2012-03-30 2018-01-25 Toray Industries Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
MX358224B (en) 2012-03-30 2018-08-10 Toray Industries Pharmaceutical composition for treatment and/or prevention of liver cancer.
WO2014014082A1 (en) 2012-07-19 2014-01-23 東レ株式会社 Cancer detection method
CN104471404B (en) 2012-07-19 2017-03-01 东丽株式会社 The detection method of cancer
JP6447130B2 (en) 2013-08-09 2019-01-09 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANIGUCHI K. ET AL.: "A Human Canalicular Multispecific Organic Anion Transporter (cMOAT) Gene Is Overexpressed in Cisplatin-Resistant Human Cancer Cell Lines with Decreased Drug Accumulation", CANCER RES., vol. 56, 15 September 1996 (1996-09-15), pages 4121 - 4129, XP003014581 *

Also Published As

Publication number Publication date
WO2006002378A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2006002378A3 (en) Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2006033664A8 (en) Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2007143752A3 (en) Targets in breast cancer for prognosis or therapy
WO2002079411A3 (en) Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
WO2004097051A3 (en) Methods for diagnosing aml and mds differential gene expression
WO2004091548A3 (en) Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2004086949A3 (en) Dna markers for management of cancer
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2295604A3 (en) Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2002024956A8 (en) Genetic markers for tumors
WO2004000094A8 (en) Predictive markers in cancer therapy
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2000070340A3 (en) Materials and methods relating to disease diagnosis
WO2005123942A3 (en) Analysis of methylated nucleic acid
WO2003070082A3 (en) Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2005047536A3 (en) Detection of genomic amplification and deletion in cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05790063

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05790063

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载